biostudies-literatureUnknownOmuro ANational Cancer Institute/National Institute of HealthNCI NIH HHS<h4>Background</h4>Methotrexate-based chemoradiotherapy is effective in primary central nervous system lymphoma (PCNSL) but carries a risk of severe neurotoxicity. In a single-arm study, a regimen with methotrexate, procarbazine, vincristine and cytarabine was combined with rituximab (R-MPV-A) and substantially reduced doses of whole-brain radiotherapy (LD-WBRT), resulting in excellent progression-free survival (PFS) and overall survival (OS). Because R-MPV-A had never been tested without radiation, we sought to evaluate the efficacy of R-MPV-A with and without LD-WBRT, as well as determining if such low radiotherapy doses influenced disease control and/or neurotoxicity.<h4>Methods</h4>Patients were randomized to receive R-MPV-A alone (Chemo arm) or combined with LD-WBRT (ChemoRT arm), givNeuro-oncologynoaf221https://www.ebi.ac.uk/biostudies/studies/S-EPMC12904153biostudies-literatureMulticenter Randomized Phase II Study of R-MPV-A Chemoimmunotherapy With or Without Low-Dose Whole-Brain Radiotherapy for Newly-Diagnosed Primary CNS Lymphoma.PMC12904153U10 CA180868U10 CA180822U10CA180868U10CA180822Wefel JSWerner-Wasik MBovi JALallana ECOmuro ACorn BWAneja SRogers CLDonnelly EDCorrea DIwamoto FMStruve TDRosenblum MGrommes CMehta MPYu HMDeAngelis LMPeereboom DMPolley MCWon MfalseMulticenter Randomized Phase II Study of R-MPV-A Chemoimmunotherapy With or Without Low-Dose Whole-Brain Radiotherapy for Newly-Diagnosed Primary CNS Lymphoma.<h4>Background</h4>Methotrexate-based chemoradiotherapy is effective in primary central nervous system lymphoma (PCNSL) but carries a risk of severe neurotoxicity. In a single-arm study, a regimen with methotrexate, procarbazine, vincristine and cytarabine was combined with rituximab (R-MPV-A) and substantially reduced doses of whole-brain radiotherapy (LD-WBRT), resulting in excellent progression-free survival (PFS) and overall survival (OS). Because R-MPV-A had never been tested without radiation, we sought to evaluate the efficacy of R-MPV-A with and without LD-WBRT, as well as determining if such low radiotherapy doses influenced disease control and/or neurotoxicity.<h4>Methods</h4>Patients were randomized to receive R-MPV-A alone (Chemo arm) or combined with LD-WBRT (ChemoRT arm), giv2025-01-01T00:00:00Z2025 Nov2026-07-15T18:02:21.858Z2026-07-08T03:08:24.488ZS-EPMC129041534118931510.1093/neuonc/noaf221